A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)

  • Kenealy, Melita (Primary Chief Investigator (PCI))
  • Lai, Li Hoon (Project Manager)

Project: Research

Project Details

Effective start/end date5/08/2131/12/24


  • Diffuse large B-cell lymphoma (DLBCL)
  • Haematological malignancy
  • Clinical trial